Firecrest eConsent shortlisted in best technological development in Clinical Trials category
ICON plc, (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that its Firecrest eConsent Solution has been selected as a finalist for the Best Technological Development in Clinical Trials in the 2015 Scrip Awards. The award winners will be announced at a ceremony in London on December 2nd.
Firecrest eConsent is a next-generation electronic informed consent solution that incorporates key recommendations from the FDA’s recent draft guidance on informed consent. The e-Consent solution is a component of ICON’s new ICONIK Informatics hub and is designed to enhance the engagement of patient populations in the development process. One of the critical parts to improving this engagement is improving the informed consent process.
Addressing the FDA’s recommendation for a more patient centric approach to presenting clinical trial information, ICON’s Firecrest eConsent employs videos and visual aids to assist in the explanation of complex scientific concepts and medical terms found in trial protocols. These educational techniques were developed based on research by Carnegie Mellon University, and have been systematically tested, to facilitate optimal patient comprehension and information retention. Firecrest eConsent enables patients to access materials via portals or through other online channels provided by the sponsor, giving patients more time to independently review and prepare questions for the physician before subsequently consenting to participate in the trial.
The annual Scrip Awards acknowledge and applaud the pharmaceutical industry’s highest achievers across all parts of the value chain, and recognise both corporate and individual achievement. The awards are open to any research-based pharmaceutical or biotechnology company as well as third party companies that supply services to the pharmaceutical industry.
About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 81 locations in 37 countries and has approximately 11,300 employees.